Schering-Plough Faces Criminal Case; Off-Label Promotion May Be One Count
Executive Summary
A criminal investigation of Schering-Plough's marketing practices includes off-label promotion, the company disclosed May 30
You may also be interested in...
Good Reprint Practices: FDA’s Draft Guidance Aims For Middle Ground
A newly released FDA draft guidance detailing a roadmap for acceptable dissemination of information on off-label drug use implies that companies need to garner enough data for a new drug application before distributing content
Schering Subsidiary Takes Fall For Criminal Charges Under DoJ Settlement
Schering-Plough's settlement of off-label promotion and Medicaid fraud charges with the Boston U.S. Attorney's office places criminal responsibility with a Schering shell subsidiary
Schering doubles litigation reserves
Schering-Plough added $250 mil. to its litigation reserves in the second quarter largely in connection with the Boston U.S. Attorney's investigation of the company, Schering said July 21. Schering disclosed the criminal investigation into off-label promotion, Medicaid rebate evasion and obstruction of justice in 2003 (1"The Pink Sheet" June 2, 2003, p. 12). The company's total litigation reserves of $500 mil. represent the firm's estimate of the funds necessary to resolve the matter. The additional funds may also be used for separate inquiries by the U.S. Justice Department and several states into wholesale pricing practices...